Effects of cholecystokinin and caerulein on human eating behavior and pain sensation: a review.
Since the mid-1970s, evidence has accumulated that cholecystokinin (CCK) has a role as a neuromodulator or neurotransmitter in the central nervous system as well as in the periphery. CCK has been shown to have a variety of effects on gastrointestinal functions and is one of the main candidates for a role as a peripheral negative feedback signal to stop feeding behavior. CCK produces satiety not only in animals but also in man: it reduces appetite and activation arising from the preparation of a meal and inhibits intake of liquid and solid food in both lean and obese subjects. The closely related peptide caerulein has similar effects. The site of action of peripherally administered CCK seems to be on an abdominal organ innervated by gastric vagal branches and relayed to the brain by afferent vagal fibres, since selective gastric vagotomy blocks the satiety effect, but pharmacological antagonism of vagal motor effects or lesions of the ventromedial hypothalamus do not. CCK also may have a role in the regulation of pain perception. In mice, CCK and caerulein were shown to produce a decrement in response to noxious stimulation after peripheral and central administration. In man, caerulein was demonstrated to relieve pain originating from biliary and renal colic as well as from cancer and ischemia. A series of studies in healthy man revealed that caerulein also alleviates experimentally induced cutaneous pain. Data from animal studies suggest that CCK-like peptides not only are able to produce analgesic effects on their own, but also are involved in the modulation of opioid systems mediating analgesia. Further study of these effects of CCK should elucidate the regulatory connections between the life-sustaining functions of feeding and pain sensation.
D000700:Analgesics; D000818:Animals; D001067:Appetite Depressants; D002490:Central Nervous System / Q000187:drug effects; D002108:Ceruletide / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology*; D004064:Digestive System / Q000187:drug effects; D004285:Dogs; D004723:Endorphins / Q000502:physiology; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D000882:Haplorhini; D006801:Humans; D006815:Hunger / Q000187:drug effects; D008297:Male; D051379:Mice; D009434:Neural Pathways / Q000187:drug effects; D009765:Obesity / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D012528:Satiety Response / Q000187:drug effects; D012844:Sincalide / Q000494:pharmacology; D014630:Vagus Nerve / Q000187:drug effects
D000700:Analgesics; D001067:Appetite Depressants; D004723:Endorphins; D002108:Ceruletide; D002766:Cholecystokinin; D012844:Sincalide